Submitted by Anonymous (not verified) on 25 September 2026 - 11:30
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 22, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 22, Status: Authorised